Harmony’s sleep disorder drug Wakix gets US label extensionHarmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom Share XHarmony’s sleep disorder drug Wakix gets US label extensionhttps://pharmaphorum.com/news/harmonys-narcolepsy-drug-gets-extended-cataplexy/
FDA approves Jazz Pharmaceuticals’ narcolepsy therapyThe FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy, Share XFDA approves Jazz Pharmaceuticals’ narcolepsy therapyhttps://pharmaphorum.com/news/fda-approves-jazz-pharmaceuticals-narcolepsy-therapy/
Jazz targets US launch of SCLC drug after FDA grants fast reviewPharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for Share XJazz targets US launch of SCLC drug after FDA grants fast reviewhttps://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/
PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinSpain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin Share XPharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinhttps://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalsThe EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’ Share XNovartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalshttps://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/
Priority review voucher prices fall again after Spark’s $110m saleVoucher prices have fallen since their 2015 peak Share XPriority review voucher prices fall again after Spark’s $110m salehttps://pharmaphorum.com/news/spark-sells-priority-review-voucher-to-jazz/
EUSA Pharma looks to further in-licensing to build growthSpecialist company EUSA Pharma is looking for new medicines to develop after getting two cancer drugs recommended by European Share XEUSA Pharma looks to further in-licensing to build growthhttps://pharmaphorum.com/news/uks-eusa-pharma-looks-bolster-pipeline/